公开(公告)号：US20210069114A1

公开(公告)日：2021-03-11

申请号：US16640789

申请日：2018-08-30

Applicant: NOVARTIS AG

Inventor： Markus KRUMME ,  Hans DE WAARD ,  Klaus-Peter MOLL ,  Adrian ACHMIDT ,  Julien TAILLEMITE

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K9/00 ,  A61K31/192

Abstract: A method for preparing granules a slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.

公开(公告)号：US20210069150A1

公开(公告)日：2021-03-11

申请号：US16898071

申请日：2020-06-10

Applicant: NOVARTIS AG

Inventor： Bruno GALLI ,  Jean-Marie GLANTZMANN ,  Arnaud GRANDEURY ,  Klaus-Peter MOLL ,  Martin MUELLER- ZSIGMONDY ,  Karsten PUTZBACH ,  Dirk SPICKERMANN ,  Hubert THOMA ,  Mike UFER

IPC: A61K31/404 ,  A61K9/28 ,  A61K9/20 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/16 ,  A61K9/50 ,  A61K47/38

Abstract: Drug products in the form of modified release formulations comprising the drug substance (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

公开(公告)号：US20230355582A1

公开(公告)日：2023-11-09

申请号：US18355618

申请日：2023-07-20

Applicant: NOVARTIS AG

Inventor： Bruno GALLI ,  Jean-Marie GLANTZMANN ,  Arnaud GRANDEURY ,  Klaus-Peter MOLL ,  Martin MUELLER-ZSIGMONDY ,  Karsten PUTZBACH ,  Dirk SPICKERMANN ,  Hubert THOMA ,  Mike UFER

IPC: A61K31/404 ,  A61K9/28 ,  A61K9/20 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/16 ,  A61K9/50 ,  A61K47/38

CPC classification number: A61K31/404 ,  A61K9/28 ,  A61K9/2004 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/1652 ,  A61K9/1682 ,  A61K9/2072 ,  A61K9/50 ,  A61K9/5089 ,  A61K47/38

Abstract: Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

公开(公告)号：US20200222325A1

公开(公告)日：2020-07-16

申请号：US16640756

申请日：2018-08-30

Applicant: NOVARTIS AG

Inventor： Markus KRUMME ,  Hans DE WAARD ,  Klaus-Peter MOLL ,  Adrian SCHMIDT ,  Frantz ELBAZ ,  Peter KLEINEBUDDE

IPC: A61K9/16 ,  A61K45/06 ,  A61K9/20 ,  A61K9/48

Abstract: In a method for preparing at least partially dried granules, an API, a base powder, and a granulation liquid are fed to a granulator. The API, the base powder and the granulation liquid are mixed within the granulator to produce an API/base powder/granulation liquid mixture. This liquid mixture within the granulator is heated to a heating temperature (TH) that exceeds an evaporation temperature (TE) of the granulation liquid contained in an API/base powder/granulation liquid mixture to allow at least a part of the granulation liquid contained in the API/base powder/granulation liquid mixture to evaporate in order to obtain at least partially dried granules containing at least the API and the base powder. The at least partially dried granules are discharged from the granulator.